GlobeNewswire

Sky9 Capital Announces the Addition of Chay, Teh, Xu, and Zeng to its Advisory Board

Dela

HONG KONG, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Sky9 Capital, a leading China venture capital firm, announced that China industry veterans KS Chay, Dr. Kok Peng Teh, Bob Xu, and Jason Zeng have joined its Advisory Board to provide strategic advice and foster long-term partnerships.

KS Chay is Founder and Chairman of Enspire Capital, and previously he co-founded Singapore's first Nasdaq-listed technology company, Creative Technology Ltd (SGX:C76). Dr. Kok Peng Teh is currently Senior Advisor and Board Member for China International Capital Corporation, and he was President of Government of Singapore Special Investments (GIC) for over a decade until 2011. Mr. Bob Xu co-founded New Oriental Education & Technology Group (NYSE:EDU), the largest provider of private education in China, and is one of China's most successful angel investors having founded ZhenFund in 2010. Mr. Jason Zeng co-founded Tencent Holdings Ltd (HK:0700) and is currently Chairman of the angel-stage investment firm Decent Capital.

"We are honored to have industry veterans like KS Chay, Dr. Kok Peng Teh, Bob Xu, and Jason Zeng join our firm as our board of advisors," said Ron Cao, Founder and Managing Director of Sky9 Capital. "Mr. Chay and Dr. Teh come from a strong institutional approach to investing and can provide us with great guidance on how to continue to build out our organization. Bob and Jason are two of China's most successful entrepreneurs, so we gain great insights from their operational background as well as inspiration on how to build great businesses together with entrepreneurs."

Founded by China venture capital veteran Ron Cao, Sky9 Capital's mission is to partner with the next generation of entrepreneurs to create world-class companies that also have societal impact. With over 17 years of VC experience in both the US and China, Ron has invested in some of China's leading technology companies including: Tujia, China's largest AirBnB player; FangDuoDuo, China's largest online-to-offline real estate transaction platform; PPDai, China's largest pure-play microlending platform; and QingCloud, China's leading enterprise-grade cloud computing platform.  Ron has been named by Forbes China as one of China's "Top Venture Capitalists" over multiple years and is honored by the World Economic Forum as one of its "Young Global Leaders".

Sky9 Capital's senior team consists of additional partners with strong venture capital and start-up experience. The team of Wei Hao, Jing Wang, Jonathan Qiu, and Tony Lo, have collectively over 30 years of venture capital experience in the US and China, and they previously worked at world-class technology companies such as Intel, Trilogy, Cisco, and Tencent. Their investments include PinDuoDuo, FaceU, Rong360, ZhaoGangWang, MaMaDaV, FangDuoDuo, JuMei, JingFuZhi, LuckyPai, and Dianping.

Sky9 Capital has completed six investments in its new fund, including ZhaoYouWang, the largest B2B marketplace for petroleum-related products in China; EZbuy, the leading Chinese cross-border e-commerce platform targeting the Southeast Asia market; and eBroker, the leading online platform for wealth management.

About Sky9 Capital 
Sky9 Capital is a leading early-stage China-focused technology venture capital firm. With its mission to partner with bold innovators to build world-class companies together and to make a positive impact on the world, Sky9 Capital specializes in the consumer Internet, enterprise, and deep technology sectors.  With presence in Beijing, Shanghai, Shenzhen, and Silicon Valley, our firm approaches investing with a global perspective and selectively partners with early-stage companies that have exceptional founding teams, disruptive and scalable business models, or innovative and transformational technology. For more information, please visit www.sky9capital.com.

Contact: Anthony Lo
Phone Number: +86-21-5238-3699
Email: tony@sky9capital.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sky9 Capital via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum